165 related articles for article (PubMed ID: 32274889)
1. Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population-based study in Sweden.
Orrason AW; Westerberg M; Garmo H; Lissbrant IF; Robinson D; Stattin P
BJU Int; 2020 Jul; 126(1):142-151. PubMed ID: 32274889
[TBL] [Abstract][Full Text] [Related]
2. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study.
Stattin P; Sandin F; Thomsen FB; Garmo H; Robinson D; Lissbrant IF; Jonsson H; Bratt O
Eur Urol; 2017 Jul; 72(1):125-134. PubMed ID: 27481175
[TBL] [Abstract][Full Text] [Related]
3. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
Akre O; Garmo H; Adolfsson J; Lambe M; Bratt O; Stattin P
Eur Urol; 2011 Sep; 60(3):554-63. PubMed ID: 21664039
[TBL] [Abstract][Full Text] [Related]
4. Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.
Heering M; Berg KD; Brasso K; Iversen P; Røder MA
Surg Oncol; 2017 Mar; 26(1):21-27. PubMed ID: 28317581
[TBL] [Abstract][Full Text] [Related]
5. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
6. Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer.
Crawley D; Garmo H; Rudman S; Stattin P; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
BJU Int; 2018 Feb; 121(2):209-216. PubMed ID: 28418195
[TBL] [Abstract][Full Text] [Related]
7. Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7.
Fosså SD; Wiklund F; Klepp O; Angelsen A; Solberg A; Damber JE; Hoyer M; Widmark A;
Eur Urol; 2016 Oct; 70(4):684-691. PubMed ID: 27025586
[TBL] [Abstract][Full Text] [Related]
8. Treatment with curative intent and survival in men with high-risk prostate cancer. A population-based study of 11 380 men with serum PSA level 20-100 ng/mL.
Ladjevardi S; Berglund A; Varenhorst E; Bratt O; Widmark A; Sandblom G
BJU Int; 2013 Mar; 111(3):381-8. PubMed ID: 22758210
[TBL] [Abstract][Full Text] [Related]
9. Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation.
Feldman AS; Meyer CP; Sanchez A; Krasnova A; Reznor G; Menon M; Kibel AS; Choueiri TK; Lipsitz SR; Sun M; Trinh QD
J Urol; 2017 Nov; 198(5):1061-1068. PubMed ID: 28552709
[TBL] [Abstract][Full Text] [Related]
10. Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study.
Robinson D; Garmo H; Lissbrant IF; Widmark A; Pettersson A; Gunnlaugsson A; Adolfsson J; Bratt O; Nilsson P; Stattin P
Eur Urol; 2018 Apr; 73(4):502-511. PubMed ID: 29254629
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
[TBL] [Abstract][Full Text] [Related]
12. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
[TBL] [Abstract][Full Text] [Related]
13. The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study.
Matthes KL; Pestoni G; Korol D; Van Hemelrijck M; Rohrmann S
Urol Oncol; 2018 Jun; 36(6):309.e15-309.e23. PubMed ID: 29576269
[TBL] [Abstract][Full Text] [Related]
14. Increased curative treatment is associated with decreased prostate cancer-specific and overall mortality in senior adults with high-risk prostate cancer; results from a national registry-based cohort study.
Aas K; Dorothea Fosså S; Åge Myklebust T; Møller B; Kvåle R; Vlatkovic L; Berge V
Cancer Med; 2020 Sep; 9(18):6646-6657. PubMed ID: 32750229
[TBL] [Abstract][Full Text] [Related]
15. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study.
Pettersson A; Robinson D; Garmo H; Holmberg L; Stattin P
Ann Oncol; 2018 Feb; 29(2):377-385. PubMed ID: 29161337
[TBL] [Abstract][Full Text] [Related]
16. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
17. Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study.
Cazzaniga W; Garmo H; Robinson D; Holmberg L; Bill-Axelson A; Stattin P
BJU Int; 2019 Mar; 123(3):421-428. PubMed ID: 30253031
[TBL] [Abstract][Full Text] [Related]
18. Temporal changes in survival in men with
Westerberg M; Franck Lissbrant I; Damber JE; Robinson D; Garmo H; Stattin P
Acta Oncol; 2020 Jan; 59(1):106-111. PubMed ID: 31526166
[No Abstract] [Full Text] [Related]
19. Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model.
Thurtle DR; Greenberg DC; Lee LS; Huang HH; Pharoah PD; Gnanapragasam VJ
PLoS Med; 2019 Mar; 16(3):e1002758. PubMed ID: 30860997
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer outcomes for men who present with symptoms at diagnosis.
Beckmann KR; O'Callaghan ME; Ruseckaite R; Kinnear N; Miller C; Evans S; Roder DM; Moretti K;
BJU Int; 2017 Jun; 119(6):862-871. PubMed ID: 27489140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]